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DBackground: Renal impairment portends adverse outcomes in patients undergoing valvular heart surgery.
The relationship between renal dysfunction in patients undergoing transcatheter aortic valve replacement
(TAVR) is incompletely understood.
Methods: A retrospective review of 1336 patients undergoing surgical aortic valve replacement (SAVR;
2002-2012) and 321 patients undergoing TAVR (2007-2012) was performed. Patients were divided into 3
glomerular filtration rate (GFR) groups: GFR greater than 60 mL/min, GFR 31 to 60 mL/min, and GFR 30
mL/min or less. Logistic and linear regression analysis was performed to estimate the TAVR effect on outcomes.
Risk adjustments were made using the Society for Thoracic Surgeons (STS) predicted risk of mortality (PROM).
Results: TAVR patients were older (82 vs 65 years; P<.001), had a poorer ejection fraction (48% vs 53%;
P<.001), were more likely female (45% vs 41%; P ¼ .23), and had a higher STS PROM (11.9% vs 4.6%;
P<.001). In-hospital mortality rates for TAVR and SAVR were 3.5% and 4.1%, respectively (P¼ .60), a result
that marginally favors TAVR after risk adjustment (adjusted odds ratio¼ .52, P¼ .06). In SAVR patients, worse-
ning preoperative renal failure was associated with increased in-hospital mortality (P ¼ .004) and hospital
(P<.001) and intensive care unit (ICU) (P<.001) lengths of stay. In contrast, worsening renal function did not
influence in-hospital mortality (P¼ .78) and hospital (P<.23) and ICU (P¼ .88) lengths of stay in TAVRpatients.
Conclusions: Worsening renal function was associated with increased in-hospital mortality, hospital length of
stay, and ICU length of stay in SAVR patients, but not in TAVR patients. This unexpected finding may
have important clinical implications in patients with aortic stenosis and preoperative renal dysfunction.
(J Thorac Cardiovasc Surg 2013;146:1399-407)Earn CME credits at
http://cme.ctsnetjournals.org
Preexisting renal dysfunction (RD) is common among pa-
tients undergoing surgical aortic valve replacement
(SAVR), with up to 75% of patients having mild (47.7%),
moderate (26.7%), or severe (2.5%) renal impairment.1
Moreover, we and others have shown that preoperative RD
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The Journal of Thoracic and Carwith in-hospital mortality of 2.9% in patients with no RD,
15% in patients with severe RD, and 17% in patients
requiring hemodialysis.1-5 In this patient demographic in
which RD is prevalent, treatment modalities that minimize
the deleterious effect on kidney function are preferred.
Recently, transcatheter aortic valve replacement (TAVR)
has emerged as a promising therapeutic alternative for
high-risk patients with severe aortic stenosis.2,3 Despite
the allure, impaired renal function at baseline, as
measured by estimated glomerular filtration rate (GFR),
represents a strong independent predictor of adverse short-
and long-term outcome in TAVR patients.4 Furthermore,
most studies focus on severe RD and end-stage renal disease
(ESRD); consequently, the relationship with lesser degrees
of RD for TAVR has been incompletely characterized.5,6
The objective of this study was to use GFR as an overall
measure of kidney function to analyze short-, mid-, and
long-term outcomes within SAVR and TAVR patients with
varying degrees of preoperative renal impairment.METHODS
Subjects and Sample
Medical records for all consecutive isolated aortic valve replacements
between January 1, 2002, and September 12, 2012, at Emory Healthcarediovascular Surgery c Volume 146, Number 6 1399
Abbreviations and Acronyms
AKI ¼ acute kidney injury
EF ¼ ejection fraction
ESRD ¼ end-stage renal disease
GFR ¼ glomerular filtration rate
ICU ¼ intensive care unit
OR ¼ odds ratio
PARTNER ¼ Placement of Aortic Transcatheter
Valve
PROM ¼ predicted risk of mortality
RD ¼ renal dysfunction
SAVR ¼ surgical aortic valve replacement
STS ¼ Society for Thoracic Surgeons
TAVR ¼ transcatheter aortic valve replacement
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DHospitals were gathered for analysis. The time frame includes the entire
series of isolated TAVR cases (2007-2012; n ¼ 321) and SAVR cases
(2002-2012; n ¼ 1336). Three patients were excluded from the analysis
because of irretrievable creatinine levels, a component of the primary study
variable. This sample of patients was included in the institution’s Society
for Thoracic Surgeons (STS) Adult Cardiac Database. This study was
Health Insurance Portability and Accountability Act compliant, and its
approval was subject to Institutional Review Board review.
Measurements
The primary study variables were surgery type (SAVR or TAVR) and
GFR class stratified by classification defined by the National Kidney Foun-
dation: mild or normal (GFR>60), moderate (30<GFR  60), or severe
or dialysis (GFR  30 or preoperative dialysis).7 The GFR was estimated
according to the Modification of Diet in Renal Disease study equation. Pre-
operative, operative, and postoperative outcomes were summarized by
these 2 variables. Preoperative variables of interest are listed in Table 1,
and operative and postoperative variables are shown in Table 2.
Missing data among preoperative predictors were present in small quan-
tities: body mass index (n ¼ 9, 0.5%), hematocrit (n ¼ 78, 4.7%), hemo-
globin (n ¼ 81, 4.9%), hemoglobin A1c (n ¼ 292, 17.6%), height (n ¼ 2,
0.1%), weight (n ¼ 1, 0.1%), ejection fraction (n ¼ 88, 5.3%), and pre-
dicted risk of mortality (n ¼ 9, 0.5%). When adjusting for the covariates
with missing data in regression models, a multiple imputation technique
was used by which ‘‘placeholder’’ values were imputed by a maximum
likelihood algorithm for the missing values. This process was repeated
10 times, and the regression estimates from these imputations were com-
bined and reported. The goal of the imputation is to maximize the use of
the existing data, not to recreate the missing data.
Statistical Analysis
Comparisons of study variables across GFR classes within the strata of
TAVR and within the strata of SAVR were made within surgery type using
analysis of variance for numerical variables and c2 tests for categorical vari-
ables (Tables 1 and 2). This studywas not designed as a superiority study, but
rather to examine different patterns within SAVR and within TAVR groups.
Changes in GFR from baseline to discharge were evaluated using paired t-
tests. Also, Kaplan-Meier analysis was used to estimate long-term survival
end points at various postoperative points of time. Also, to control for selec-
tion bias, multivariable logistic (for clinical end points) and linear (for nu-
merical outcomes) models were constructed to test for the independent
effects of surgery and GFR burden. Adjustments were end point specific,
pre-hoc, and included patient age, white race, chronic lung disease, redo1400 The Journal of Thoracic and Cardiovascular Surstatus, ejection fraction (EF), insulin dependence, sex, immunocompro-
mised, emergent status, stroke, and peripheral vascular disease. Logistic
modelswerefit for death, stroke, dialysis, andworsening renal failure. Linear
regression models were used for length of stay and intensive care unit (ICU)
hours. Adjusted odds ratios and 95% confidence intervals were calculated
for each comparison. SAVR was the reference group for surgery compari-
sons, and ‘‘normal’’ or ‘‘mild’’ was the reference for GFR burden. Three
separate models were constructed for each outcome: (1) a model comparing
the effect of SAVR with TAVR on all patients, (2) a comparison of GFR
burden within SAVR, and (3) a comparison of GFR burden within TAVR.
Cox proportional hazards regression was used for the following: (1) to
test the effects of surgery type and GFR burden on long-term survival and
(2) to test for interaction between surgery and GFR group. A significant
interaction was detected (P<.001), meaning that the effect of GFR burden
on survival was different in TAVR patients than in SAVR patients. Thus, a
stratified regression approach was used to characterize the interaction.
Separate Cox models were fit within SAVR and TAVR patients separately.
Adjusted hazard ratios and 95% confidence intervals were reported after
adjustment with the STS predicted risk of mortality score (PROM), a
known covariate of survival.
The Social Security Death Index, in conjunction with hospital records,
was queried for death dates of each study patient. The death dates were
collected on February 29, 2012; patients alive on that date were considered
censored for survival analyses. Patients operated on after this date had no
long-term survival follow-up and, thus, were excluded from all survival
analyses.
RESULTS
Baseline Characteristics
Table 1 describes baseline demographic and clinical char-
acteristics of preoperative variables for SAVR and TAVR,
stratified by GFR burden. The average ages for TAVR and
SAVR patients were 82.2  8.2 and 65.2  14.6 years,
respectively. TAVR patients were older than SAVR patients,
but also had a lower EF across varying degrees of GFR
burden and higher STS PROM. The PROM increased for
both SAVR and TAVR with increased GFR burden: TAVR
(mild, 0.10  0.05; moderate, 0.13  0.07; and severe/dial-
ysis, 0.21  0.13) and SAVR (mild, 0.03  0.02; moderate,
0.06  0.05; and severe/dialysis, 0.14  0.12).
Preoperative and Postoperative Clinical End Points
Operative and postoperative clinical end points for SAVR
and TAVR, stratified by GFR burden, are described in Table
2. For SAVR, the incidence of new dialysis and worsening
renal failure increased with worsening renal function
(P<.001 for both). However, for TAVR, there was no sta-
tistical significancewith worsening preoperative renal func-
tion and need for new postoperative dialysis and RD
(P ¼ .78). Similarly, for SAVR, ventilation and ICU hours
increased with worsening renal function (P < .001 for
both), whereas for TAVR, there was no association between
ventilation hours (P¼ .87) or ICU hours (P¼ .89) and GFR
burden. The average hospital length of stay for the SAVR
patients increased with the worsening of the GFR class
(mild, 7.6 5.8 days; moderate, 9.7 7.7 days; severe/dial-
ysis, 13.0 9.8 days; P<.001), but this was not the case for
TAVR patients (P ¼ .15).gery c December 2013
TABLE 1. Demographic and clinical characteristics by surgery type and GFR burden
SAVR (N ¼ 1336) TAVR (N ¼ 321)
None/mild
(n ¼ 915)
Moderate
(n ¼ 320)
Severe/dialysis
(n ¼ 101) P value
None/mild
(n ¼ 159)
Moderate
(n ¼ 139)
Severe/Dialysis
(n ¼23 P value
Age, y 63.1  15.1 72.7  10.0 60.7  15.1 <.001 81.7  9.1 83.4  6.9 79.6  8.4 .047
BMI, kg/m2 28.4  6.2 28.7  6.5 28.7  7.3 .71 25.9  4.8 27.3  6.1 28.0  6.3 .037
EF 54.2  12.8 51.5  14.2 51.7  12.0 .004 49.0  12.8 48.8  14.8 39  16.4 .005
PROM 0.03  0.02 0.06  0.05 0.14  0.12 <.001 0.10  0.05 0.13  0.07 0.21  0.13 <.001
White 744 (81.3) 283 (88.4) 46 (45.5) <.001 147 (92.5) 130 (93.5) 19 (82.6) .19
Female sex 333 (36.4) 167 (52.2) 48 (47.5) <.001 61 (38.4) 72 (51.8) 9 (39.1) .06
Cerebrovascular disease 140 (15.3) 75 (23.4) 13 (12.9) .002 48 (30.2) 43 (30.9) 12 (52.2) .10
COPD 172 (18.8) 89 (27.8) 25 (24.7) .035 77 (48.4) 69 (49.6) 11 (47.8 .90
Diabetes 212 (23.2) 115 (35.9) 47 (46.5) <.001 69 (43.3) 59 (42.5) 12 (52.2) .68
Preoperative creatinine 0.93  19 1.37  0.28 5.4  2.9 <.001 0.92  0.20 1.40  0.29 3.4  2.0 <.001
Dyslipidemia 552 (60.3) 206 (64.4) 50 (49.5) .028 144 (90.6) 123 (88.5) 23 (100.0) .22
Hypertension 692 (75.6) 278 (86.9) 96 (95.1) <.001 148 (93.1) 135 (97.1) 22 (95.7) .28
PVD 78 (8.5) 39 (12.2) 21 (20.8) <.001 53 (33.3) 44 (31.7) 14 (60.9) .022
CVA 77 (8.4) 36 (11.3) 7 (6.9) .24 25 (15.7) 19 (13.7) 8 (34.8) .038
Previous CABG 98 (10.7) 52 (16.3) 17 (16.8) .014 65 (40.9) 46 (33.1) 9 (39.1) .38
Previous valve 84 (9.2) 33 (10.3) 10 (9.9) .83 31 (19.5) 26 (18.7) 10 (43.5) .021
Redo 179 (19.6) 79 (24.7) 26 (25.7) .08 80 (50.3) 61 (43.9) 11 (47.8) .54
Preoperative IABP 2 (0.2) 1 (0.3) 2 (2.0) .022 0 (0.0) 2 (1.4) 1 (4.4) .09
Data are given as mean  SD or number (percentage). GFR, Glomerular filtration rate; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement;
BMI, body mass index; EF, ejection fraction; PROM, predicted risk of mortality; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease; CVA, cere-
brovascular disease; CABG, coronary artery bypass grafting; IABP, intra-aortic balloon pump.
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the severe RD for SAVR (n¼ 61) and TAVR (n¼ 8) groups
were 60% and 34%, respectively. The corresponding death
rates for SAVR and TAVR were 14.8% (n ¼ 9) and 0%
(n ¼ 0), respectively.
Figure 1 depicts in-hospital mortality for SAVR and
TAVR patients grouped by varying degrees of RD. For
SAVR patients, worsening GFR was associated withTABLE 2. Operative and postoperative clinical end points by surgery typ
SAVR (N ¼ 1336)
None/mild
(n ¼ 915)
Moderate
(n ¼ 320)
Severe/dialysis
(n ¼ 101)
Intraoperative IABP 37 (4.0) 25 (7.8) 9 (8.9)
Postoperative IABP 8 (0.9) 2 (0.6) 0 (0.0)
Postoperative transfusion 573 (62.6) 250 (78.1) 86 (85.2)
Stroke 24 (2.6) 7 (2.2) 6 (5.9)
Atrial fibrillation 220 (24.0) 110 (34.4) 31 (30.7)
Pneumonia 31 (3.4) 19 (5.9) 9 (8.9)
New dialysis 10 (1.1) 9 (2.8) 10 (9.9)
Worsening RF 29 (3.2) 14 (4.4) 12 (11.9)
Bleeding 31 (3.4) 12 (3.8) 7 (6.9)
Crossclamp Time, min 81.2  24.4 78.5  23.9 87.0  23.9
Ventilation, h 34.1  109.3 49.7  129.2 95.6  169.4
ICU, h 73.1  121.6 102.4  147.2 167.4  207.5
Discharge creatinine 0.95  0.29 1.27  0.48 4.44  2.57
LOS 7.6  5.8 9.7  7.7 13.0  9.8
Contrast load – – –
GFR, Glomerular filtration rate; SAVR, surgical aortic valve replacement; TAVR, transca
ICU, intensive care unit; LOS, length of stay.
The Journal of Thoracic and Carincreased in-hospital mortality (mild, 2.6%; moderate,
4.1%; severe, 8.9%; P ¼ .004). Worsening GFR, however,
was not associated with increased in-hospital mortality for
TAVR patients (mild, 3.8%; moderate, 2.9%; severe,
4.4%; P ¼ .89). The solid line and dot in the figure repre-
sent the STS PROM stratified by varying degrees of RD.
For both SAVR and TAVR, a stepwise increase in the STS
PROM was appreciated with worsening renal function.e and GFR burden
TAVR (N ¼ 321)
P value
None/mild
(n ¼ 159)
Moderate
(n ¼ 139)
Severe/dialysis
(n ¼ 23) P value
.009 8 (5.0) 5 (3.6) 0 (0.0) .49
.60 1 (0.6) 0 (0.0) 0 (0.0) .60
<.001 66 (41.5) 68 (48.9) 9 (39.1) .38
.12 2 (1.3) 2 (1.4) 1 (4.4) .53
.001 13 (8.2) 9 (6.5) 2 (8.7) .83
.012 9 (5.7) 3 (2.2) 0 (0.0) .17
<.001 3 (1.9) 3 (2.2) 0 (0.0) .78
<.001 5 (3.1) 3 (2.2) 0 (0.0) .63
.21 1 (0.6) 2 (1.4) 0 (0.0) .68
.009 – – – –
<.001 30.6  85.3 35.0  145.6 20.4  17.2 .87
<.001 69.9  100.6 76.7  153.5 76.0  58.1 .89
<.001 0.90  0.23 1.31  0.48 3.06  1.53 <.001
<.001 6.6  5.2 6.9  6.6 9.2  7.3 .15
– 118  64 111  80 70  34 .01
theter aortic valve replacement; IABP, intra-aortic balloon pump; RF, renal failure;
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FIGURE 1. In-hospital mortality and Society for Thoracic Surgeons
(STS) predicted risk of mortality (PROM), based on the degree of kidney
dysfunction in patients undergoing surgical aortic valve replacement
(SAVR) and transcatheter aortic valve replacement (TAVR).
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SAVR and TAVR stratified by varying degrees of RD. For
SAVR, there was a stepwise decrease in long-term survival
with worsening renal function (P ¼ .001). Decreased renal
function, however, was not associated with increased long-
termmortality in TAVR (P¼ .94). The 6-month, 1-year, and
4-year survival rates for all SAVR patients were 91.6%,
89.2%, and 82.4%, respectively. For all TAVR patients,
6-month, 1-year, and 4-year survival rates were 87.2%,
79.3%, and 26.8%, respectively.
Table 3 depicts GFR burden by contrast load, procedure,
and TAVR access. The range of contrast used in our study
was 1 to 150 mL (mean, 109  61 mL). Irrespective of
the amount of contrast used, postoperative GFR increased
relative to preoperative GFR. Furthermore, when adjusting
for covariates and STS predicted risk of renal failure,
contrast load was not associated with increased incidence
of renal failure (odds ratio [OR], 0.998; P¼ .80) or dialysis
(OR, 0.998; P ¼ .72). Both SAVR and TAVR resulted in
increased GFR, with a change of 2.6 and 5.3, respectively.
The change in GFR was greater in TAVR than in SAVR
(P ¼ .02).
In all patients, the adjusted odds ratio for death was 0.47
when comparing TAVR with SAVR (Table 4). In SAVR pa-
tients, the adjusted odds ratio for death was 2.6 when
comparing severe/dialysis with normal patients. In TAVR
patients, the odds ratio was 1.01 when comparing severe/1402 The Journal of Thoracic and Cardiovascular Surdialysis with normal patients. Worsening GFR increased
the hazard for death for SAVR but not for TAVR. In
SAVR patients with moderate and severe RD, the hazards
for death were 77% and 180% higher than the hazards
for patients with normal renal function, respectively.
DISCUSSION
A strong association exists between valvular heart dis-
ease, particularly aortic stenosis, and renal dysfunction,
with up to 75% of patients having mild, moderate, or severe
RD.1 In patients with ESRD, dystrophic calcification of the
aortic annulus and leaflets occurred rapidly and frequently,
with onset 10 to 20 years earlier than in the general popula-
tion.8 In patients with RD undergoing SAVR, we have pre-
viously shown that impaired GFR is associated with a
predictable stepwise increase in adverse short-, mid-, and
long-term outcomes.1 Because TAVR emerges as an alter-
native treatment modality for inoperative or high-risk pa-
tients with severe aortic stenosis, the relationship between
varying degrees of RD and postoperative outcome is incom-
pletely understood. In this study, we investigated the
relationship between varying degrees of RD on short-,
mid-, and long-term outcomes in both TAVR and SAVR pa-
tients. The following points highlight our results: (1) TAVR
mitigates the effect of moderate and severe RD on short-
and long-term survival; (2) SAVR and TAVR increased
postoperative GFR, but a greater improvement was appreci-
ated after TAVR; and (3) contrast load for TAVR was not
associated with increased renal failure or dialysis.
Survival
Although previous studies have detailed short- and
mid-term survival in both SAVR and TAVR, data regarding
mortality stratified by GFR are sparse. Ameta-analysis con-
ducted by Khatri and colleagues,9 including 49 TAVR
studies (16,063 patients), revealed 30-day and 1-year sur-
vival rates of 91.9% and 79.2%, respectively. TAVR pa-
tients in our study had slightly better 30-day survival
(at 96.5%) and similar 1-year survival (at 79.3%). Our sur-
vival results were more in congruence with the landmark
Placement of Aortic Transcatheter Valve (PARTNER) trial
for high-risk patients demonstrating 30-day and 1-year all
cause mortality from TAVR of 3.4% and 24.2%, respec-
tively.3 Survival in TAVR patients with renal dysfunction,
however, is less understood. It is increasingly recognized
that impaired baseline renal function and periprocedural
acute kidney injury (AKI) portend adverse short- and
long-term outcomes in TAVR patients. In 213 TAVR pa-
tients with baseline RD, Bagur and colleagues5 report an
AKI incidence of 11.7% and a 4-fold increased risk of post-
operative mortality.5 The incidence of new or worsening
renal failure in our TAVR group was 2.5% (Table 2).
Furthermore, Webb and colleagues10 reveal chronic renal
failure as an independent predictor for cumulative lategery c December 2013
FIGURE 2. Kaplan-Meier survival estimates stratified by renal dysfunction for surgical aortic valve replacement (SAVR) and transcatheter aortic valve
replacement (TAVR).
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preoperative and postoperative RD after TAVR, short- and
mid-term outcome with varying degrees of GFR has not
been described. Our results extend on previous findings
by stratifying outcome after TAVR by varying degrees of
renal function.
The most provocative results from our study relate to
mortality in the TAVR group. In-hospital mortality for
mild, moderate, and severe renal dysfunction in our studyThe Journal of Thoracic and Carwas 3.8%, 2.9%, and 4.4% (Figure 1, P ¼ .89), respec-
tively. There was no association with in-hospital mortality
and worsening renal function. On the contrary, in our
SAVR group, worsening renal function was associated
with a stepwise increase in short-term mortality, at 2.6%,
4.1%, and 8.9% for mild, moderate, and severe RD, respec-
tively. Although worsening renal function is strongly asso-
ciated with increased mid- and long-term mortality in our
SAVR group, Kaplan-Meier survival estimates for TAVRdiovascular Surgery c Volume 146, Number 6 1403
TABLE 3. Preoperative and postoperative GFR burden by contrast
load, procedure, and TAVR access
Variable
Sample
size
Preoperative
GFR
Discharge
GFR Change
P
value
Contrast load, mL
1-74 86 57.4 63.1 5.7 <.001
75-149 141 60.7 65.4 4.7 .003
150þ 73 70.7 76.9 6.2 .037
SAVR 1333 71.7 74.3 2.6 <.001
TAVR 321 61.6 67.0 5.3 <.001
Transfemoral TAVR 198 61.7 67.3 5.5 <.001
Transapical TAVR 99 60.3 66.4 6.1 <.001
Transaortic 20 61.9 59.2 2.6 .60
GFR, Glomerular filtration rate; TAVR, transcatheter aortic valve replacement; SAVR,
surgical aortic valve replacement.
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ship (Figure 2). It appears that TAVR mitigates the effect of
moderate and severe RD on short- and mid-term survival.
After risk adjustment, the odds ratio estimate for death in
severe/dialysis SAVR patients versus patients with no RD
was 2.64 (Table 4, P < .05), whereas the observed
outcome/expected outcome ratio for similar TAVR patients
was 1.0. Our SAVR results corroborate prior findings by our
group examining short- and long-term outcome with vary-
ing degrees of renal function.1
Similar observations were noted with other important
outcome variables, specifically, new renal failure, ventilator
and ICU hours, and hospital length of stay (Table 2). For
these variables, patients in the SAVR group experienced a
stepwise increase in adverse outcome as renal function
declined. On the contrary, worsening renal function was
not associatedwith worsening outcomes in the TAVRgroup.Improved GFR
Acute renal failure is a common complication after car-
diac surgery, occurs in up to 30% of patients, and is a
powerful predictor of adverse outcome independent of all
other factors.11 In TAVR patients, the incidence of AKI
ranges from 11.7% to 28%, depending on baseline
patient characteristics.5,12 Proper identification of renal
dysfunction is critical in predicting postoperative
outcomes, and GFR appears to be the optimal measure forTABLE 4. Adjusted odds ratio estimates using direct adjustments
All patients (n ¼ 1657) SAVR patients (n ¼
TAVR vs SAVR Moderate vs normal Severe
Death 0.47 (0.23-0.95)* 1.12 (0.58-2.18) 2.
Stroke 0.33 (0.12-0.92)* 0.61 (0.25-1.48) 1.
New dialysis 0.57 (0.21-1.56) 2.25 (0.83-6.08) 11.
New renal failure 0.47 (0.20-1.08) 1.19 (0.59-2.41) 3.
ICU, h 49.9 h* 7.7
LOS, d 3.2* 1.3*
SAVR, Surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; IC
1404 The Journal of Thoracic and Cardiovascular Suroverall kidney function.13 Although onset of AKI is an
important prognostic variable after cardiac surgery, the ef-
fect of SAVR and TAVR on postoperative GFR is incom-
pletely understood.
In our study, we used a nonionic low osmolar contrast
agent (Isovue; Bracco Diagnostics Inc, Princeton, NJ) to
examine preoperative and postoperative GFR after SAVR
and TAVR. Both SAVR and TAVR increased postoperative
GFR at discharge, and it appears that TAVR resulted in a
greater increase in GFR (change in GFR: SAVR, 2.6 mL/
min per 1.73m2; TAVR, 5.3 mL/min per 1.73m2). Our anal-
ysis combined all access approaches for TAVR, including
transfemoral (n ¼ 198, 62%), transapical (n ¼ 99, 31%),
and transaortic (n ¼ 20, 6%). Both transfemoral and
transapical approaches increased postoperative GFR of
near-equal magnitude, whereas transaortic approaches did
not increase GFR (Table 3). Other investigators have seen
similar trends in improvement of GFR after SAVR and
TAVR. Aregger and colleagues12 evaluated 54 patients after
TAVR and reported GFR improvements in 56% of patients.
In a larger study by Van Linden and colleagues,14 including
270 patients after transapical TAVR, improved GFR was
also noted in more than 50% of patients. In our study,
GFR was improved in 51% of SAVR and 59.5% of
TAVR patients, respectively (P ¼ .007).
There is a tight association between aortic stenosis and
renal dysfunction, presumably from pathomechanisms
that promote calcium deposition on aortic leaflets after
cyclical mechanical stress.8 In patients with ESRD, dystro-
phic calcification of the aortic annulus and leaflets occurs
rapidly and frequently, thereby worsening aortic stenosis.
On the other hand, severe aortic stenosis with decreased
flow to the kidneys has been suggested as a contributing
mechanism for impaired glomerular filtration rate.12 As a
result, it is conceivable renal dysfunction begets aortic ste-
nosis and aortic stenosis subsequently begets renal dysfunc-
tion. The results from our study are insightful in that
correction of aortic stenosis by either SAVR or TAVR im-
proves overall kidney function in most patients, and may
stop the cycle of aortic stenosis begetting renal dysfunction
and vice versa. This underlies the importance and urgency
of addressing aortic stenosis in patients with renal dysfunc-
tion to improve renal flow.1336) TAVR patients (n ¼ 321)
/dialysis vs normal Moderate vs normal Severe/dialysis vs normal
64 (1.15-6.04)* 0.72 (0.21-2.41) 1.01 (0.11-9.52)
61 (0.57-4.56) 1.12 (0.15-8.27) 3.69 (0.24-57.62)
94 (4.19-34.02)* 1.00 (0.18-5.52) –
76 (1.65-8.56)* 0.61 (0.13-2.83) –
77.6* 2.9 10.8
4.4* 0.1 2.5
U, intensive care unit; LOS, length of stay. *P<.05.
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In patients with aortic stenosis in whom preexisting renal
dysfunction is prevalent, treatment modalities that mini-
mize the deleterious effect on kidney function are preferred.
SAVR requires cardiopulmonary bypass, a recognized risk
factor for AKI after cardiac surgery.15 On the other hand,
TAVR avoids cardiopulmonary bypass, but subjugates the
kidneys to a potentially nephrotoxic contrast agent during
the procedure.16 The mean amount of contrast used in
TAVR patients for our study was 109  61 mL. Patients
with none to mild RD received the most amount of contrast
(118  64 mL), whereas patients with severe RD received
the least amount of contrast (70  34 mL) (Table 2).
Regardless of the amount of contrast used in our study,
GFR improved for most patients. Moreover, contrast load
was not associated with increased incidence of renal failure
(OR, 0.998; P ¼ .80) or new-onset dialysis (OR, 0.998;
P ¼ .72) in our multivariable analysis with renal function
as an outcome variable. This result also holds when adjust-
ing for the STS predicted risk of renal failure.
Our results are corroborated by several smaller TAVR
studies. Podolecka and colleagues17 examined preoperative
and postoperative creatinine and GFR in 39 TAVR patients
with a mean contrast volume of 187  91 mL. The contrast
amount did not correlate with decreased renal function.
Additional studies by Strauch and colleagues18 in 30 trans-
apical TAVR patients also did not demonstrate a relation-
ship between contrast amount (median, 115 mL) and
kidney injury.
Our study involving 343 TAVR patients extends on previ-
ous studies and further suggests that reasonable amounts of
contrast in the range of 1 to 150 mL is not associated with
increased renal failure or dialysis. The authors recognize,
however, the potential dose-related nephrotoxic potential
of using contrast agents and recommend judicious use in pa-
tients with severe renal dysfunction.Limitations
Several important limitations are noteworthy when
extrapolating results from this study. This represents an
observational retrospective database study with inherent
limitations. The study was designed as an intragroup com-
parison to determine trends in outcome with varying de-
grees of renal dysfunction. Future propensity-matched
studies comparing TAVR with SAVR are warranted. This
study, however, does provide valuable insight into trends
within TAVR and trends within SAVR. We used a single
measurement for preoperative and postoperative GFR.
Although there is probably little variation in preoperative
renal function, we recognize that postoperative GFR is a dy-
namic variable and cannot exclude that further measure-
ments during the hospitalization may reveal either
improved or worse renal function. For our analysis, weThe Journal of Thoracic and Carelected to use GFR at discharge, with the assumption that
renal function had adequately stabilized to reveal a higher
or lower incidence of AKI. Last, the authors appreciate
the potential for a type II error. Our sample sizes are moder-
ately large, and power calculations are not advisable in
retrospective, uncontrolled studies. Our analysis did
achieve statistical significance in several predefined end
points, suggesting adequate power in the comparisons.
This study was not designed as a superiority study, but
rather it was designed to look for different patterns of effects
on outcomes within TAVR and SAVR subgroups.CONCLUSIONS
This represents a large series of SAVR (n ¼ 1336) and
largest series of TAVR (n ¼ 343) patients examining
short-, mid-, and long-term outcomes in patients with vary-
ing degrees of preoperative RD and postoperative renal
function. Worsening renal function was associated with
increased in-hospital and long-term mortality, hospital
length of stay, and ICU length of stay in SAVR patients,
but not in TAVR patients. TAVRmitigates the effect of renal
dysfunction on short- and long-term survival, SAVR and
TAVR increased postoperative GFR, and contrast load
was not associated with renal failure of dialysis. These find-
ings may have important clinical implications when deliber-
ating between SAVR and TAVR in aortic stenosis patients
with preoperative renal dysfunction.
We thank staff members Kim Baio for project oversight and
Iman Aziz for data extraction.References
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Dr Wilson Szeto (Philadelphia, Pa). Tom, fantastic presenta-
tion, well-written manuscript. Thank you in advance for sending
the manuscript to us for review. You and your colleagues at Emory
should be congratulated on such a well-timed study. As you know,
for patients with severe renal impairment, there is really not a
whole lot of data regarding the role of TAVR in this patient popula-
tion. As you know, that is an exclusion for the PARTNER trial.
You have nicely demonstrated that, in this population in a center
of excellence, mortality can be kept at 4.4% despite their signifi-
cant comorbidities. So, I congratulate you on that.
A few comments in terms of the data and I will follow up with 3
questions. First, I would reconsider your conclusion that TAVR
mitigates the long-term effect of severe renal dysfunction on
survival outcome. In your survival curve in the severe renal
impairment group undergoing TAVR, there were I think 3 patients
at 1-year follow-up. I would caution as calling that long-term
outcome and survival improvement.
Number 2, as you so elegantly displayed on your preoperative
demographic slides, these clearly are 2 separate sets of patients:
the surgical patients and the TAVR patients were different. In
your manuscript, you share that the 4-year survival in the surgical
group was 82.4% versus 26% in the TAVR group. So, clearly,
again, this emphasizes that these are different cohorts.
But, let’s focus on why we are interested in this abstract, which
is the role of TAVR in patients with severe renal dysfunction. So, 3
questions. I will ask them in sequence, and I will give you a chance
to answer.
The first one. Just out of curiosity, what was the percentage or
the ratio of TF versus transapical and direct aortic? And, as you
know, this is not so much a reflection of technique but also a
reflection of patient comorbidities. Can you comment on that in
terms of your experience in the TAVR group?1406 The Journal of Thoracic and Cardiovascular SurDr Nguyen. Thank you, Dr Szeto, for your thoughtful and
constructive comments of the presentation and the manuscript.
Of our patients, 60% were transfemoral, 30% were transapical,
and the rest were transaortic. When we looked at access as a mea-
sure of outcome, we found that both transfemoral and transapical
access increased postoperative GFR of near-equal magnitude. We
did not appreciate this increase with the transaortic subgroup.
Dr Szeto. Second question. Looking specifically at patients
with severe renal impairment, because that is really the group
we are interested in because this is the set of patients that we do
not have a whole lot of data on, you stated in your manuscript
that development of new postoperative renal failure was signifi-
cantly higher in surgical AVR patients. At the same time, the
preoperative baseline creatinine was also higher in that group.
So, the saying goes, not all renal impairment patients are the
same. Can you further elaborate on the specific characteristics of
their renal impairment?What was the breakdown between patients
with severe renal impairment but not on dialysis versus the patients
on dialysis? And for patients on dialysis, how long had they been
on dialysis?
Dr Nguyen. That is a great question. Unfortunately, the data
were queried from the STS database, so we do not have informa-
tion on the duration of hemodialysis. We do know that, in our
SAVR subgroup, roughly 60% were on hemodialysis, and interest-
ingly enough, the death rate for our SAVR group on hemodialysis
was 14%.
Looking at our TAVR subgroup, approximately 34% were on
hemodialysis, and our death rate was 0%.
Dr Szeto. And, the last question is sort of a bigger picture
patient selection question. Your group has shown that we can do
this safely in a 30-day period with a 4.4% mortality, even in
patients with severe renal insufficiency. As you know, over the
last 4 years, we have struggled with the question of futility versus
utility. There are patients, as you know, that are so sick and
considered futile for TAVR, the so-called cohort Cs. Based on
your data, what can you share with the rest of us in terms of
recommendations for patient selection when someone comes in
your clinic who has aortic stenosis whom you think are either
high risk or inoperable and have severe renal insufficiency or
dialysis? Should we be treating these patients with TAVR or
not? Other groups, such as the Dallas group, have had disap-
pointing early data, and they have stopped doing so. I would like
to thank the Association for the privilege to discuss this paper.
DrNguyen.Your last comment is really the million dollar ques-
tion, specifically, what do we do with patients with end-stage renal
disease with severe aortic stenosis? At Emory, we treat each of
these patients on a case-by-case basis. So, for the young ESRD pa-
tient with a relatively low STS score and minimal comorbidities,
then we will approach TAVR with relatively low reluctance. On
the other hand, our research and other publications suggested
that patients with severe COPD and end-stage renal disease are
those patients that we tend to shy away from. But, for the most
part, we do try to approach these patients on a case-by-case basis,
and we do not necessarily exclude just because they have end-stage
renal disease or are on hemodialysis.
Dr Szeto. How about newly placed on hemodialysis versus
being on it for 5 to 8 years, is that also a screening tool for you
as well, the duration of time they have been on hemodialysis?gery c December 2013
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variable to consider, and we are more aggressive if a patient has
only recently been on hemodialysis.
DrHarold Lazar (Boston, Mass). As we all know, themortality
and the long-term survival for patients with chronic renal failure
on dialysis who receive a valve replacement, their 3-year survival
has been reported to be as low as 25%, and a lot of people think that
maybe TAVRmight be a good indication for that. Do you have any
long-term data, though, as far as the durability of these valves? Do
these valves last that long in patients who have chronic renal fail-
ure on dialysis, are they more prone to calcification, do they have
higher gradients?
Dr Nguyen. Unfortunately, the valves are tissue valves, and, in
theory, we assume that they will last just as long as our
bioprosthetic valves, roughly 10 to 15 years, but the reality is we
do not know. The PARTNER trial started in 2007, and we do not
have long-term data.
DrRalph Damiano (St Louis, Mo). I have a couple of questions
for you. First of all, did you look at the timing of the preoperative
cardiac catheterization in the 2 groups and whether that may have
influenced the incidence of renal insufficiency, particularly in
those that had progression of renal dysfunction? Certainly, the
UVA group has shown that if you perform the catheterization right
before the surgery, it is associated with worsening renal function as
opposed to doing it at some distance prior to surgery. At least I
know in our institution for valve procedures, they tend to come
in the day before and get a catheterization and then go right to
surgery. For our transcatheter valves, the catheter is often done
weeks before surgery. Have you looked at the timing of the cardiac
catheterization as a variable that may have predicted worse
outcome in patients, particularly who had an elevated creatinine
but have not yet gone on dialysis?
Dr Nguyen. As you alluded to, the TAVR workup is fairly
comprehensive and most of the patients have their workup
completed weeks prior to valve implantation. So, it is rare that
we will catheterize the patient the day prior to surgery. So, by
the time they are getting the TAVR, the potential nephrotoxic
effects of the contrast have subsided. There have been other studies
that have clumped these patient cohorts with a left heart
catheterization and then the TAVR, and they also appreciate a
slight increase in GFR postoperatively.The Journal of Thoracic and CarThe interesting point from a more philosophical stand point is
for the kidneys, what is really worse, is it the cardiopulmonary
bypass or is it the contrast load? And, our data seem to suggest
that the contrast load is less deleterious than the cardiopulmonary
bypass run. And, if you think about it also, the contrast that we
used was roughly around 150 mL. When we do a CT angiogram
of the chest, abdomen and pelvis, that is about 150 mL. So, if
you are doing a CT angiogram on a patient, it is roughly about
the same amount of contrast that we use for our TAVR patients.
We do try to be judicious about the contrast load for the patients
with severe renal dysfunction, and our average contrast load for
these patients is roughly 70 to 80 mL.
Dr Damiano. I will ask my question again. You compared the 2
groups, surgical versus transcatheter, and my question is, was the
timing of the cardiac catheterization different in those 2 groups,
because at least in our institution it is, and would that have
influenced at all your results?
Dr Nguyen. This study was not designed as a superiority study.
It was designed as an intergroup comparison looking at trends
within the surgical AVR and within the TAVR group. To
actually compare the 2 groups, the best approach would be a
propensity-matched analysis in which we do not have a large
enough patient population, although this is the largest series
known to date looking at TAVR patients with varying degrees of
renal dysfunction.
DrDamiano.And, then, one quick last question.Youmentioned
that in the dialysis patients that you had much higher mortality in
the surgical than in the transcatheter group, because you said in
patients on dialysis there were no deaths. Admittedly, it is a small
group.
Dr Nguyen. Correct.
Dr Damiano. What was the cause of death in these dialysis
patients and did that differ between the 2 groups? When you are
talking about the potential mortality benefit of transcatheter valve
replacement in these patients with end-stage renal disease, where
is that benefit? Is this early or late death, was the cause of death
somehow related to progression of renal dysfunction, or was this
all-cause mortality? I want to get some feeling for when did the
patients die and what was the cause of death?
Dr Nguyen. For those specific end-stage renal disease patients
on hemodialysis, we looked at short-term mortality.diovascular Surgery c Volume 146, Number 6 1407
